Marshall Wace’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Marshall Wace’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,960,103	Closed	-$25M	–	3227
2023 Q1	$25M	Buy	+5,960,103	New	+$30.9M	0.05%	386
2022 Q2	–	Sell	-862,383	Closed	-$4.03M	–	4096
2022 Q1	$4.03M	Buy	862,383 +773,293	+868%	+$2.31M	0.01%	1538
2021 Q4	$221K	Buy	+89,090	New	+$218K	﹤0.01%	3127
2017 Q1	–	Sell	-15,000	Closed	-$60K	–	985
2016 Q4	$60K	Buy	+15,000	New	+$62.2K	﹤0.01%	946

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Marshall Wace's CTIC Position: Q2 2023 in Review

Marshall Wace sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 5,960,103 shares — an estimated $25M sold.

Marshall Wace first reported a position in CTIC in Q4 2016 and held it in 4 quarters. The position peaked at $25M in Q1 2023. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Marshall Wace reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Marshall Wace sold 5,960,103 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $25M.
Marshall Wace first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2016 and held it in 4 quarters.
Marshall Wace's CTI BioPharma Corp. (DE) Common Stock position peaked at $25M in Q1 2023.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Marshall Wace's 13F filing for Q2 2023, filed 14 Aug 2023.